Tonix Pharma ( (TNXP) ) has issued an update.
Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising results of its TNX-1700 candidate in cancer treatment. Collaborating with Columbia University scientists, the study demonstrated that TNX-1700 enhanced the effects of anti-PD-1 therapy, leading to tumor regression and prolonged survival in animal models. These findings highlight TNX-1700’s potential to revolutionize immunotherapy by targeting specific immune suppressor cells, offering hope for improved cancer treatments.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
